An ATP-competitive EphA2 tyrosine kinase inhibitor, ALW-II-41-2730, possesses obvious in vitro and in vivo anti-tumor effects in lung cancer31–33, melanoma34, triple-negative breast cancer35, and intrahepatic cholangiocarcinoma36. Here, EPHA2 is linked to neoplasm.